Onco Support

geneOmbio’s Onco Support panels include cancer diagnosis and treatment guide based on genetic testing. We provide Sanger sequencing and NGS based tests to detect different type of cancer and refine treatment plans.

SERVICES

METHOTREXATE

This test identifies the mutations in MTHFR and RFC genes that are linked to methotrexate toxicity

TPMT

TPMT genotyping results have predicted thiopurine drug toxicity in a variety of disorders, including rheumatic disease, acute lymphoblastic leukemia, renal transplantation, and Crohn’s disease.

OXALIPLATIN

Associated with chemo sensitivity and clinical outcome in patients with advanced colorectal cancer, treated by 5-FU/oxaliplatin- based chemotherapy is screened

EGFR

EGFR mutation Test allows the physician to prescribe the most suitable therapy for a patient with locally advanced or metastatic non-small cell lung cancer

C-KIT

C-KIT assay (EXON 17) confirms the diagnosis of Systemic Mastocytosis. KIT mutations represent molecular prognostic marker in AML with inv(16)and t(8;21).

IRMA- IMATINIB

In CML-CP patients receiving imatinib first-line, mutation analysis is recommended in case of failure or suboptimal response using European Leukemia Net (ELN) criteria

BRAF

It is designed to help select patients for treatment with vemurafenib, an oral medicine designed to treat patients whose melanoma tumors harbor a mutated form of the BRAF gene

K-RAS

These mutations can indicate prognosis and may be predictive of drug response (administration of anti-epidermal growth factor receptor (EGFR) therapy of metastatic colorectal cancer (mCRC)

5-FU

5-FU genotyping is the most comprehensive clinically available test for assessing the risk of toxicity due to 5-FU/capecitabine–based chemotherapy.

MPL-S505/W515

Diagnose essential thromobocythemia or idiopathic myelofibrosis in patients with a negative JAK2 v617f test result.

IDH1/IDH2

Detect IDH1 and IDH2 exon 4 mutations in whole blood or bone marrow. May have prognostic significance in patients with hematologic malignancies, depending on the clinical and genetic context.

Interested in our work and services?

Leave your contact details and we will get back to you as earliest

×
Any questions? Get a call back
Get a Call Back